Search

Your search keyword '"Yassine, Hadi M."' showing total 806 results

Search Constraints

Start Over You searched for: Author "Yassine, Hadi M." Remove constraint Author: "Yassine, Hadi M."
806 results on '"Yassine, Hadi M."'

Search Results

1. Prevalence of hepatitis B and C viruses among migrant workers in Qatar

6. Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradient

7. Seroprevalence of herpes simplex virus type 1 and type 2 among the migrant workers in Qatar

10. Follow up and comparative assessment of IgG, IgA, and neutralizing antibody responses to SARS-CoV-2 between mRNA-vaccinated naïve and unvaccinated naturally infected individuals over 10 months

11. Short- and longer-term all-cause mortality among SARS-CoV-2- infected individuals and the pull-forward phenomenon in Qatar: a national cohort study

13. Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study

15. Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational study

16. Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study

19. Evaluation of Efficacy of Surface Coated versus Encapsulated Influenza Antigens in Mannose–Chitosan Nanoparticle-Based Intranasal Vaccine in Swine

20. Metabolic predictors of COVID-19 mortality and severity: a survival analysis

28. Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections

29. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar

30. Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage

35. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar

36. Protection of natural infection against reinfection with SARS-CoV-2 JN.1 variant

38. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

40. SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112,941 individuals

41. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy

42. Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar

47. Prevalence of hepatitis A virus among migrant workers in Qatar: A national study.

48. Estimating protection afforded by prior infection in preventing reinfection: applying the test-negative study design.

49. Antibody‐dependent enhancement (ADE) of SARS‐CoV‐2 in patients exposed to MERS‐CoV and SARS‐CoV‐2 antigens.

50. Follow‐Up and Comparative Assessment of SARS‐CoV‐2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA‐1273 Heterologous Booster Vaccination.

Catalog

Books, media, physical & digital resources